# Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/long-term-2-year-safety-and-efficacy-of-tralokinumab-in-adults-with-moderate-to/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Andrew Blauvelt,Richard G. Langley,J.‐P. Lacour,Darryl Toth,Vivian Laquer,Stefan Beissert,Andreas Wollenberg,Pedro Herranz,Andrew Pink,Ketty Peris,Stine Fangel,Le Gjerum,Joshua Corriveau,Hidehisa Saeki,Richard B. Warren,Eric L. Simpson,Kristian Reich |
| Citations | 75 |
| DOI | 10.1016/j.jaad.2022.07.019 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://doi.org/10.1016/j.jaad.2022.07.019 |
| OpenAlex ID | https://openalex.org/W4286255965 |
| PMID | 35863467 |
| Type | article |
| Year | 2022 |

## Paper authors

- [Pedro Herranz](https://scholariq.org/researchers/pedro-herranz/)

## Paper primary topic

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)

## Paper topics

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.